Dare Bioscience (DARE) PT Lowered to $5 at Brookline Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts DARE Hot Sheet
Price: $0.66 --0%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
Brookline Capital Markets analyst Kemp Dolliver lowered the price target on Dare Bioscience (NASDAQ: DARE) to $5.00 (from $7.00) while maintaining a Buy rating.
You May Also Be Interested In
- Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference
- Edwards Lifesciences (EW) PT Raised to $118 at UBS
- TaskUs, Inc (TASK) PT Raised to $8 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
